Table 2.

Effect of several inhibitors on thrombin-, PAR₁-AP- and PAR₄-AP-induced platelet aggregation (% ± SEM)

	Control DMSO≤0.2%	U73122 10 µM	LY294002 50 µM	Ro31-8220 10 µM	PP2 10 µM	Staurosporine 1 µM
Thrombin 0.2 U·mL−1	83.3 ± 1.7	1.2 ± 0.2*	48.2 ± 7.9*	5.6 ± 0.8*	48.8 ± 6.7*	13.8 ± 3.5*
PAR1-AP 25 µM	78.3 ± 0.8	0.8 ± 0.1*	37.9 ± 2.9*	8.9 ± 2.4*	45.6 ± 4.3*	5.9 ± 0.5*
PAR4-AP 150 µM	85.5 ± 2.1	0.9 ± 0.2*	46.4 ± 8.3*	1.0 ± 0.2*	73.3 ± 5.0	5.8 ± 0.7*

Washed platelets were stimulated with thrombin, PAR₁-AP or PAR₄-AP in the absence or presence of the phospholipase C inhibitor U73122, PI3K inhibitor LY294002, protein kinase C inhibitor Ro 31-8220, Src kinase inhibitor PP2 and the broad spectrum inhibitor of protein kinases staurosporine, and aggregation was recorded as described in Methods. Data were derived from four different experiments.

^*P < 0.05 versus control activated samples.